What is Claimed is:

1. A chimeric peptide having an amino acid sequence comprising or consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:69, or SEQ ID NO:70.

2. The chimeric peptide of claim 1, wherein the peptide is less than about 250 amino acids in length.

3. The chimeric peptide of claim 1, wherein said peptide has an amino acid sequence comprising or consisting of SEQ ID NO:1.

4. The chimeric peptide of claim 1, wherein said peptide has an amino acid sequence comprising or consisting of SEQ ID NO:2.

5. The chimeric peptide of claim 1, wherein said peptide has an amino acid sequence comprising or consisting of SEQ ID NO:52.

6. The chimeric peptide of claim 1, wherein said peptide has an amino acid sequence comprising or consisting of SEQ ID NO:53.

7. A chimeric peptide having an amino acid sequence comprising SEQ ID NO:70.

8. A chimeric peptide having an amino acid sequence consisting of SEQ ID NO:70.

9. A chimeric peptide having an amino acid sequence comprising SEQ ID NO:69.

10. A chimeric peptide having an amino acid sequence consisting of SEQ ID NO:69.

11. The chimeric peptide of any one of claims 1 to 10, wherein said peptide is fused with an immunoglobulin Fc region.

12. A pharmaceutical composition comprising the chimeric peptide of any of claims 1 to 11, and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12, wherein the composition further comprises a glucose-lowering agent, and a pharmaceutically acceptable carrier.

14. A nucleic acid molecule encoding the chimeric peptide of any of claims 1 to 11, wherein the nucleic acid molecule further comprises an expression control element in operable linkage that confers expression of the nucleic acid molecule encoding the peptide *in vitro*, in a cell or *in vivo*.

15. A vector comprising the nucleic acid molecule of claim 14; wherein the vector optionally is a viral vector.

16. A transformed or host cell line that expresses the chimeric peptide of any of claims 1 to 11.

17. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for reducing glucose levels in a subject.

18. The use of claim 17, wherein the medicament is prepared to be administered to said subject in combination with a supplementary therapy.

19. The use of claim 18, wherein said supplemental therapy is a weight loss surgery, gastric bypass, gastrectomy, gastric banding, gastric balloon, or gastric sleeve.

20. The use of claim 18, wherein said supplemental therapy is a glucose lowering agent, insulin, GLP1 analogue, biguanide, sulphonylurea, thiazolidinedione, a dipeptidyl peptidase-4 (DPP-4) inhibitor, a bromocriptine formulation, a bile acid sequestrant, metformin, a thiazolidinedione (TZD), a SGLT-2 inhibitor, or any combination thereof.

21. The use of claim 20, wherein said biguanide or sulphonylurea is selected from the group consisting of tolbutamide, chlorpropamide, acetohexamide, tolazamide, glibenclamide, glipizide and any combination thereof.

22. The use of claim 20, wherein said thiazolidinedione is rosiglitazone or pioglitazone, or combination thereof.

23. The use of claim 20, wherein said bile acid sequestrant is colesevelam.

24. The use of claim 18, wherein said supplemental therapy is to be administered prior to, contemporaneously with or following said medicament.

25. The use of claim 17, wherein the glucose levels are blood glucose levels.

26. The use of claim 17, wherein the subject has nonalcoholic fatty liver disease (NAFLD).

27. The use of claim 17, wherein the subject has nonalcoholic steatohepatitis (NASH).

28. The use of claim 17, wherein the subject has a fasting plasma glucose (FPG) level of greater than 100 mg/dl.

29. The use of claim 17, wherein the subject has an FPG level of 125 mg/dl or above.

30. The use of claim 17, wherein the subject has an FPG level of between about 100 and 125 mg/dl.

31. The use of claim 17, wherein the glucose levels are reduced by at least 5%.

32. The use of claim 17, wherein the subject has a hemoglobin A1c (HbA1c) level above 6%.

33. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for the treatment of a hyperglycemic condition in a subject.

34. The use of claim 33, wherein the hyperglycemic condition is diabetes.

35. The use of claim 33, wherein the hyperglycemic condition is insulin-dependent (type I) diabetes.

36. The use of claim 33, wherein the hyperglycemic condition is type II diabetes.

37. The use of claim 33, wherein the hyperglycemic condition is gestational diabetes.

38. The use of claim 33, wherein the hyperglycemic condition is prediabetes.

39. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for the treatment of insulin resistance in a subject.

40. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for the treatment of hyperinsulinemia in a subject.

41. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for the treatment of glucose intolerance in a subject.

42. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for the treatment of a metabolic syndrome in a subject.

43. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for the treatment of obesity in a subject.

44. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for reducing glucagon in a subject.

45. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for increasing glucose metabolism or homeostasis in a subject.

46. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for improving pancreatic function in a subject.

47. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for reducing triglycerides in a subject.

48. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for reducing cholesterol in a subject.

49. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for reducing IDL, LDL or VLDL levels in a subject.

50. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for decreasing blood pressure in a subject.

51. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for decreasing intimal thickening of the blood vessel in a subject.

52. Use of the peptide of any one of claims 1 to 11 in the manufacture of a medicament for decreasing body mass or weight gain in a subject.

53. The peptide of any one of claims 1 to 11 for use in therapy.